Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
34
DSGN Quote, Financials, Valuation and Earnings
Last price:
$9.10
Seasonality move
:
-10.52%
Day range:
$9.23 - $9.88
52-week range:
$2.60 - $10.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.60x
Volume:
220.1K
Avg. volume:
451.4K
1-year change:
47.49%
Market cap:
$518.4M
Revenue:
--
EPS (TTM):
-$1.19
Analysts' Opinion
-
Consensus RatingDesign Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $13.50, Design Therapeutics, Inc. has an estimated upside of 48.35% from its current price of $9.38.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $12.00 representing 100% downside risk from its current price of $9.38.
Fair Value
-
According to the consensus of 2 analysts, Design Therapeutics, Inc. has 48.35% upside to fair value with a price target of $13.50 per share.
DSGN vs. S&P 500
-
Over the past 5 trading days, Design Therapeutics, Inc. has underperformed the S&P 500 by -5.6% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Design Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Design Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Design Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Design Therapeutics, Inc. earnings have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter Design Therapeutics, Inc. reported earnings per share of -$0.30.
Enterprise value:
314.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.19x
EV / Free cash flow:
-5.99x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$615K
Return On Assets:
-28.44%
Net Income Margin (TTM):
--
Return On Equity:
-29.71%
Return On Invested Capital:
-29.43%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$554K | -$585K | -$615K | -$153K | -$155K | |
| Operating Income | -$82.5M | -$60.8M | -$78M | -$16.2M | -$19.3M | |
| EBITDA | -$81.9M | -$60.2M | -$77.4M | -$16.1M | -$19.2M | |
| Diluted EPS | -$1.29 | -$0.85 | -$1.19 | -$0.23 | -$0.30 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $395.3M | $348.5M | $294.5M | $257.2M | $209M | |
| Total Assets | $400.4M | $354.6M | $299.9M | $261.6M | $211.8M | |
| Current Liabilities | $5.5M | $10.4M | $12.4M | $7.4M | $11.2M | |
| Total Liabilities | $8.8M | $13.6M | $14.9M | $9.2M | $12.1M | |
| Total Equity | $391.6M | $340.9M | $285M | $252.5M | $199.7M | |
| Total Debt | $3.3M | $3.2M | $2.5M | $1.7M | $877K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$60.9M | -$46M | -$52.3M | -$9.5M | -$11.2M | |
| Cash From Investing | $45.9M | $47.7M | $36.3M | -$5.8M | $6.5M | |
| Cash From Financing | $353K | $751K | $684K | $1K | $37K | |
| Free Cash Flow | -$61.4M | -$46.4M | -$52.4M | -$9.5M | -$11.2M | |
DSGN
Sector
Market Cap
$518.4M
$28.2M
Price % of 52-Week High
88.3%
50.98%
Dividend Yield
0%
0%
Shareholder Yield
-0.12%
-1.55%
1-Year Price Total Return
47.49%
-17.58%
Beta (5-Year)
--
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$9.62
200-day SMA
Buy
Level
$5.47
Bollinger Bands (100)
Buy
Level
5.49 - 8.61
Chaikin Money Flow
Sell
Level
-10.1M
20-day SMA
Sell
Level
$9.51
Relative Strength Index (RSI14)
Buy
Level
53.08
ADX Line
Buy
Level
18.2
Williams %R
Neutral
Level
-60.0717
50-day SMA
Buy
Level
$8.14
MACD (12, 26)
Buy
Level
0.38
25-day Aroon Oscillator
Sell
Level
-40
On Balance Volume
Neutral
Level
4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (20.0808)
Buy
CA Score
(Annual)
Level (0.6054)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (6.6756)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Design Therapeutics, Inc. operates as a biotechnology company that develops therapies for serious degenerative disorders. It is created to design, develop and commercialize a novel class of small molecule therapeutic candidates (GeneTACs) designed to directly address the underlying basis of genetic disease. The company was founded by Pratik Shah and Aseem Z. Ansari on December 18, 2017 and is headquartered in Carlsbad, CA.
Stock Forecast FAQ
In the current month, DSGN has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The DSGN average analyst price target in the past 3 months is $13.50.
-
Where Will Design Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Design Therapeutics, Inc. share price will rise to $13.50 per share over the next 12 months.
-
What Do Analysts Say About Design Therapeutics, Inc.?
Analysts are divided on their view about Design Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Design Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $12.00.
-
What Is Design Therapeutics, Inc.'s Price Target?
The price target for Design Therapeutics, Inc. over the next 1-year time period is forecast to be $13.50 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is DSGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Design Therapeutics, Inc. is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of DSGN?
You can purchase shares of Design Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Design Therapeutics, Inc. shares.
-
What Is The Design Therapeutics, Inc. Share Price Today?
Design Therapeutics, Inc. was last trading at $9.10 per share. This represents the most recent stock quote for Design Therapeutics, Inc.. Yesterday, Design Therapeutics, Inc. closed at $9.38 per share.
-
How To Buy Design Therapeutics, Inc. Stock Online?
In order to purchase Design Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get DSGN Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
DSGN
Sector
P/E ratio
--
24.09x
PEG ratio
-0.19x
-0.01x
P/B ratio
2.60x
1.81x
Price / LTM sales
--
1.59x
Growth Metrics
DSGN
Sector
Revenue growth
--
4.68%
Earnings growth
-29.57%
11.06%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.34
-$0.18
Profitability
DSGN
Sector
Profitability FY 2024
-$596K
$3.6M
Return on invested capital
-29.43%
-31.84%
Return on assets
-28.44%
-28.18%
Return on equity
-29.71%
-37.63%
Earnings Date
Last Earnings Date
Nov
5
Next Earnings Date
Mar
10
Estimated Next Earnings Date
Feb
4
Balance Sheet
DSGN
Sector
Total cash
$206M
$26.3M
Short term investments
$222.9M
$26M
Total assets
$252.1M
$76.7M
Long term debt
$877K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Sell
46
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
55
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
45
CTEV alert for Jan 4
Claritev Corp. [CTEV] is down 20.7% over the past day.
Buy
60
BIDU alert for Jan 3
Baidu, Inc. [BIDU] is up 15.01% over the past day.
Sell
47
ASTS alert for Jan 4
AST Spacemobile, Inc. [ASTS] is up 14.94% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
